CareDx (CDNA) Jumps As Naveris Deal Redraws Growth Map

CareDx Inc. stocks have been trading up by 34.35 percent following upbeat transplant diagnostics outlook and renewed investor optimism.

Live Update At 17:03:44 EDT: On Thursday, July 16, 2026 CareDx Inc. stock [NASDAQ: CDNA] is trending up by 34.35%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

CDNA is trading like a name that just got a fresh catalyst. Over the past few weeks, CareDx Inc. climbed from the mid‑$20s to a close of $40.34 on 2026/07/16. That’s a powerful breakout after several sessions grinding between roughly $27 and $30.

The intraday tape on the latest session tells the story. CDNA opened near $36.43, briefly washed to $35.50, then bulls took control. By late afternoon, the stock pushed through $40, with multiple five‑minute candles holding above $38 and buyers stepping in on each dip. That’s classic momentum action, with shorts getting squeezed and late longs chasing.

Fundamentally, CareDx is still in “build for growth” mode. Trailing revenue sits around $379.8M, growing high single to low double digits annually. Gross margin near 68.9% is strong for diagnostics, but profit margins are still negative on a full‑year basis, reflecting heavy spend on R&D and sales. Leverage is low, with total debt to equity of just 0.06 and a current ratio of 3.4, so CDNA has room to ride out volatility.

For traders, this mix—high gross margin, improving cash flow, and big news catalysts—often fuels multiday momentum runs, but also sharp pullbacks once the news is fully priced in.

Why Traders Are Watching CDNA Right Now

CareDx Inc. just stacked two major strategic moves on top of already strong clinical news, and the CDNA chart is reacting exactly how momentum traders like to see.

First, the company closed its acquisition of Naveris on 2026/07/01. That brings NavDx, the only Medicare‑covered minimal residual disease (MRD) blood test for HPV‑positive head and neck and anal cancers, straight into the CareDx portfolio. For CDNA, this is more than “one more test.” Management now pegs its addressable market above $12B across transplant, specialty oncology, and cell therapy. Traders care because NavDx revenue is expected to be fast‑growing, high‑priced, and recurring, with contributions starting in Q3 2026. That kind of visibility often supports higher multiples in story stocks.

Second, right before the Naveris close, CareDx sold its global Lab Products business to Eurobio Scientific for $171.2M in cash. CDNA is essentially pruning slower, kit‑based transplant typing and monitoring products to double down on higher‑growth U.S. precision medicine testing and digital solutions. Cash from the sale adds flexibility to fund the oncology and cell therapy push that Naveris represents.

On the clinical side, CareDx is reinforcing its moat. At the 2026 American Transplant Congress, the company highlighted more than 30 abstracts and 9 oral presentations. These data sets back AlloSure, AlloMap, HeartCare, AlloSure Plus, HistoMap Kidney, and ImmuneScape across kidney, heart, lung, and multi‑organ transplants. For CDNA, that means stronger physician confidence and potentially stickier demand.

Layer on the KOAR registry analysis published in the Journal of the American Society of Nephrology, showing elevated AlloSure Kidney donor‑derived cell‑free DNA tracks with higher graft dysfunction and loss, and you get a clear message: CareDx assays are not just “nice to have,” they help stratify risk over years. That tends to support reimbursement and volumes.

One caution flag: an insider, director Hannah Valantine, sold 12,103 CDNA shares for about $279,728 on 2026/06/12, and now holds 36,686 shares. It’s not a massive sale relative to the overall float, but active traders always log insider moves as part of the tape.

Conclusion

CDNA is acting like a name transitioning from a pure‑play transplant diagnostics story into a broader precision oncology and cell therapy platform. The Naveris acquisition widens the playing field and brings in a differentiated, Medicare‑covered MRD test with recurring revenue potential. The $171.2M Lab Products sale cleans up the portfolio and adds cash that CareDx Inc. can redeploy into those higher‑growth, higher‑margin opportunities.

At the same time, the core transplant engine looks stronger, not weaker. Heavy data at the 2026 American Transplant Congress and the KOAR registry publication both support the long‑term role of AlloSure and the broader CDNA test suite in real‑world care. For traders focusing on catalysts, that combination—strategic deals plus clinical validation—is exactly what often drives multi‑week trend moves.

But no trend is straight up. CDNA has already sprinted from the mid‑$20s to the low‑$40s area in a short window, which means late buyers are vulnerable to sharp pullbacks. As Tim Sykes loves to say, “Patterns repeat, but it’s your job to recognize when the crowd is late and protect yourself by cutting losses quickly.” As millionaire penny stock trader and teacher Tim Sykes, says, “Preparation plus patience leads to big profits.”. For active traders, CareDx now sits firmly on the watchlist as a catalyst‑rich, news‑driven momentum name—one that demands strict risk rules and a clear trading plan.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

• Penny Stocks Trading Guide
• Best Penny Stocks Under $1 to Buy Today
• Top 8 Penny Stocks to Watch on Robinhood

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks